Conference Preview: NASPGHAN Annual Meeting 2025

The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) is holding its Annual Meeting from November 5–8, 2025, at the Sheraton Grand Chicago in Chicago, Illinois. Over the course of this four-day conference, pediatric gastroenterologists, hepatologists, nutrition specialists, and leading experts will gather to share the latest data, clinical updates, and evidence-based discussions across gastrointestinal, liver, and nutritional disorders in children.

Founded in 1972, NASPGHAN is the only society in North America—and the largest worldwide—dedicated to advancing research, education, and clinical practice in pediatric gastroenterology and nutrition. The meeting provides attendees with an opportunity to explore the latest findings, enhance clinical proficiency, and engage in expert discussions focused on improving outcomes in pediatric patients.

HCPLive will be on-site to provide interviews with session presenters, daily highlights of new research, and practical coverage throughout the meeting.

Sessions to Watch

Helicobacter Pylori Infection and Immune-Mediated Digestive Diseases in Children of the Americas: A Cross-Sectional Study of Comparative Prevalence

Presenters: Silvana Bonilla, Jose Vera, Ailim Carias, Carlos Cuadros, Michelle Higuera, Juan Pablo Riveros Lopez, Natali Gonzalez Rozo, Gloria Toscano, Ana Beatriz Munoz, Idalmis Aguilera, Enju Liu, Paul Harris
Overview: This study assessed the prevalence of Helicobacter pylori infection (HPI) in children with newly diagnosed immune-mediated digestive diseases (IMDD). While HPI eradication in adults helps prevent complications, the role in children remains unclear. The session will explore comparative prevalence data across the Americas and discuss implications for pediatric evaluation of IBD, celiac disease, and eosinophilic esophagitis.

Safety and Tolerability of Tenapanor in Pediatric Patients with Irritable Bowel Syndrome With Constipation: An Analysis of Blinded Safety Data From a Phase 3 Study and Its Open-Label Extension

Presenters: Nastassja Williams, Thomas Wallach, Mihaela Ringheanu, Ana Roig Cantisano, Yang Yang, Karishma Raju, Jocelyn Tabora, Susan Edelstein
Overview: This session presents preliminary, blinded safety data from the Phase 3 R-ALLY study and its open-label extension assessing tenapanor in pediatric patients with IBS-C aged 12–17 years. Attendees will learn about early safety and tolerability findings for this first-in-class, minimally absorbed therapy and its potential role in pediatric gastrointestinal care.

Characteristics Associated With Response to Teduglutide Treatment in Children With Short Bowel Syndrome–Associated Intestinal Failure: A Post Hoc Analysis of Long-Term Extension Studies

Presenters: Valeria Cohran, Beth Carter, Samuel Kocoshis, Susan Hill, Pradeep Nazarey, Ian Robinson, Brian Terreri, Robert Venick, Danielle Wendel, Paul W Wales
Overview: This session will examine patient characteristics associated with response to teduglutide in children with SBS-IF, including achievement of consistent response and sustained enteral autonomy. Attendees will gain insights into factors that may guide clinical decision-making and optimize long-term outcomes for children requiring parenteral nutrition.

Therapeutic Trial of Sucraid® (Sacrosidase) for Alleviating Gastrointestinal Symptoms in Pediatric Subjects Stratified by Duodenal Sucrase Activity Levels

Presenters: Tanaz Danialifar, Jonathan Markowitz, Eduardo Rosas-Blum, Mario Tano, Melissa Van Arsdall, Angela Shannon, Youhanna Al-Tawil, Mary Lowry, Devendra Mehta, Daniel Gelfond, Adrian Miranda, Namrata Patel-Sanchez, Rohit Kohli, Craig Friesen, Runa Watkins, Molly O’Gorman, Thomas Sferra, Lesley Small-Harary, Barbara Verga, Kevin Watson, David Gremse, Christopher Hayes, Hillary Bashaw, Aldo Maspons, Shikib Mostamand, Miguel Saps, Maryam Shambayati, Julie Khlevner, Uwe Blecker, Stephanie Oliveira, Shaija Kutty
Overview: This exploratory Phase 4 study investigated the effect of a 7-day sacrosidase trial on gastrointestinal symptoms in pediatric patients with suspected congenital sucrase-isomaltase deficiency (CSID) across a spectrum of sucrase activity. The session will discuss therapeutic responses by baseline sucrase activity, symptom frequency, and potential modifying effects of lactase deficiency.

Crossroads Between Celiac Disease and Other Autoimmune Conditions

Date/Time: Friday, November 7, 11:07 AM
Presenter: Daniel Mallon
Overview: Mallon will describe associations between celiac disease and other autoimmune conditions in children, exploring potential mechanisms linking celiac disease with the development of additional autoimmune disorders.

Optimizing Nutrition in Cholestatic Liver Disease: A Collaborative Approach

Date/Time: Friday, November 7, 11:07 AM
Presenters: Rima Fawaz, Lauren Storch
Overview: This session will review nutritional deficiencies and sarcopenia in children with cholestatic liver disease. Attendees will learn practical strategies for nutritional assessment, surveillance, and supplementation to optimize care in this patient population.

The HCPLive team will deliver comprehensive updates on-site, along with exclusive interviews and recaps of sessions directly from the meeting. Stay tuned for more throughout the week, and click here to view our continuing coverage from Chicago.

Editor's note: This summary was edited with the help of AI tools.